Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1821) 1821
Publication (98) 98
Patent (72) 72
Book Chapter (10) 10
Book Review (4) 4
Magazine Article (4) 4
Conference Proceeding (2) 2
Dissertation (2) 2
Newsletter (2) 2
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (727) 727
male (350) 350
female (341) 341
adult (293) 293
gastroenterology & hepatology (290) 290
middle aged (265) 265
animals (166) 166
virology (154) 154
infection (132) 132
aged (130) 130
index medicus (128) 128
microbiology (121) 121
infectious diseases (116) 116
antiviral agents - therapeutic use (102) 102
hepatitis c (92) 92
gastroenterology and hepatology (91) 91
hepatitis b virus (89) 89
molecular sequence data (84) 84
risk factors (81) 81
hepatitis b virus - genetics (80) 80
polymerase chain reaction (80) 80
hepacivirus - genetics (76) 76
genotype (74) 74
chemistry (72) 72
life sciences (72) 72
therapy (72) 72
hepatitis (71) 71
immunology (71) 71
treatment outcome (71) 71
adolescent (70) 70
metallurgy (70) 70
liver - pathology (68) 68
biochemistry (67) 67
hygiene (67) 67
interferon-alpha - therapeutic use (67) 67
human necessities (66) 66
medical or veterinary science (66) 66
preparations for medical, dental, or toilet purposes (66) 66
base sequence (65) 65
beer (65) 65
enzymology (65) 65
mutation or genetic engineering (65) 65
peptides (65) 65
spirits (65) 65
vinegar (65) 65
wine (65) 65
recombinant proteins (64) 64
chronic disease (63) 63
liver (63) 63
hepatitis c virus (62) 62
culture media (61) 61
hepatocellular carcinoma (61) 61
interferon (61) 61
drug therapy, combination (60) 60
compositions thereof (59) 59
microorganisms or enzymes (59) 59
organic chemistry (59) 59
propagating, preserving or maintaining microorganisms (59) 59
prospective studies (59) 59
prevalence (58) 58
cirrhosis (57) 57
replication (57) 57
hepatitis b (56) 56
hepatitis c, chronic - drug therapy (56) 56
hepatitis b virus - immunology (53) 53
dna (51) 51
france (50) 50
time factors (50) 50
hepatitis b - immunology (49) 49
ribavirin (47) 47
rna (47) 47
rna, viral - blood (47) 47
investigating or analysing materials by determining theirchemical or physical properties (46) 46
measuring (46) 46
mutation (46) 46
physics (46) 46
testing (46) 46
virus replication (46) 46
hepacivirus - immunology (45) 45
specific therapeutic activity of chemical compounds ormedicinal preparations (45) 45
hepatocellular-carcinoma (44) 44
liver cirrhosis (44) 44
alanine transaminase - blood (43) 43
dna, viral - analysis (43) 43
follow-up studies (43) 43
hepatitis b - complications (42) 42
mice (42) 42
virus diseases (42) 42
aids (41) 41
france - epidemiology (41) 41
health aspects (41) 41
hepatitis c - epidemiology (41) 41
ribavirin - therapeutic use (41) 41
virus-infection (41) 41
disease (40) 40
hepatitis b surface antigens - analysis (40) 40
hiv (40) 40
pharmacology & pharmacy (40) 40
amino acid sequence (39) 39
antiviral agents (39) 39
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1317) 1317
French (613) 613
German (18) 18
Portuguese (10) 10
Spanish (6) 6
Danish (2) 2
Chinese (1) 1
Japanese (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Impact of patatin‐like phospholipase‐3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C
by Trépo, Eric and Pradat, Pierre and Potthoff, Andrej and Momozawa, Yukihide and Quertinmont, Eric and Gustot, Thierry and Lemmers, Arnaud and Berthillon, Pascale and Amininejad, Leila and Chevallier, Michéle and Schlué, Jerome and Kreipe, Hans and Devière, Jacques and Manns, Michael and Trépo, Christian and Sninsky, John and Wedemeyer, Heiner and Franchimont, Denis and Moreno, Christophe
Hepatology, ISSN 0270-9139, 07/2011, Volume 54, Issue 1, pp. 60 - 69
Only 20% of patients with chronic hepatitis C (CHC) will develop cirrhosis, and fibrosis progression remains highly unpredictable. A recent genome‐wide... 
GENETIC-VARIATION | GENOTYPE | CIRRHOSIS | LIVER FIBROSIS | PNPLA3 | RISK | INFECTION | NATURAL-HISTORY | GASTROENTEROLOGY & HEPATOLOGY | ASSOCIATION | DISEASE PROGRESSION | Fatty Liver - pathology | Humans | Middle Aged | Hepatitis C, Chronic - physiopathology | Male | Adult | Female | France | Liver Cirrhosis - genetics | Fatty Liver - genetics | European Continental Ancestry Group - genetics | Genetic Predisposition to Disease - genetics | Interleukins - therapeutic use | Cross-Sectional Studies | Antiviral Agents - therapeutic use | Membrane Proteins - genetics | Fatty Liver - physiopathology | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Disease Progression | Belgium | Liver Cirrhosis - pathology | Polymorphism, Single Nucleotide - genetics | Aged | Liver Cirrhosis - physiopathology | Hepatitis C, Chronic - genetics | Longitudinal Studies | Germany | Lipase - genetics | Confidence intervals | Hepatitis | Liver cirrhosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta‐analysis of individual participant data
by Trépo, Eric and Nahon, Pierre and Bontempi, Gianluca and Valenti, Luca and Falleti, Edmondo and Nischalke, Hans‐Dieter and Hamza, Samia and Corradini, Stefano Ginanni and Burza, Maria Antonella and Guyot, Erwan and Donati, Benedetta and Spengler, Ulrich and Hillon, Patrick and Toniutto, Pierluigi and Henrion, Jean and Franchimont, Denis and Devière, Jacques and Mathurin, Philippe and Moreno, Christophe and Romeo, Stefano and Deltenre, Pierre and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
Hepatology, ISSN 0270-9139, 06/2014, Volume 59, Issue 6, pp. 2170 - 2177
The incidence of hepatocellular carcinoma (HCC) is increasing in Western countries. Although several clinical factors have been identified, many individuals... 
FIBROSIS | ETIOLOGY | IMPACT | DISEASE | SUSCEPTIBILITY | FATTY LIVER | RISK | CIRRHOSIS RELATIONSHIP | POLYMORPHISM | MODEL | GASTROENTEROLOGY & HEPATOLOGY | Liver Neoplasms - genetics | Membrane Proteins - genetics | Carcinoma, Hepatocellular - genetics | Humans | European Continental Ancestry Group | Models, Genetic | Polymorphism, Single Nucleotide | Hepatitis C, Chronic - complications | Liver Cirrhosis, Alcoholic - complications | Lipase - genetics | Klinisk medicin | Clinical Medicine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text PNPLA3 (rs738409 C>G) is a common risk variant associated with hepatocellular carcinoma in alcoholic cirrhosis
by Trepo, Eric and Guyot, Erwan and Ganne‐Carrie, Nathalie and Degre, Delphine and Gustot, Thierry and Franchimont, Denis and Sutton, Angela and Nahon, Pierre and Moreno, Christophe
Hepatology, ISSN 0270-9139, 04/2012, Volume 55, Issue 4, pp. 1307 - 1308
DOMAIN-CONTAINING 3 | GASTROENTEROLOGY & HEPATOLOGY | FATTY LIVER-DISEASE | PROGRESSION | Carcinoma, Hepatocellular - epidemiology | Humans | Middle Aged | Male | Liver Neoplasms - epidemiology | Carcinoma, Hepatocellular - genetics | Adult | Female | Retrospective Studies | France | Liver Cirrhosis, Alcoholic - ethnology | Carcinoma, Hepatocellular - ethnology | Genetic Predisposition to Disease - genetics | Liver Neoplasms - genetics | Comorbidity | Membrane Proteins - genetics | Risk Factors | Genotype | Liver Neoplasms - ethnology | Liver Cirrhosis, Alcoholic - genetics | Liver Cirrhosis, Alcoholic - epidemiology | Belgium | Genetic Predisposition to Disease - ethnology | Aged | Genetic Variation - genetics | Lipase - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence
by Bizollon, T and Ahmed, S N S and Radenne, S and Chevallier, M and Chevallier, P and Parvaz, P and Guichard, S and Ducerf, C and Baulieux, J and Zoulim, F and Trepo, C
Gut, ISSN 0017-5749, 02/2003, Volume 52, Issue 2, pp. 283 - 287
Background and objective: A proportion of liver transplanted patients with recurrent chronic hepatitis have a sustained virological response to combination... 
INFECTION | PREDICTOR | RECIPIENTS | GASTROENTEROLOGY & HEPATOLOGY | ALPHA THERAPY | HCV-RNA | Liver - virology | Recurrence | Hepatitis C - therapy | Liver - pathology | Liver Transplantation | Antiviral Agents - therapeutic use | Humans | Liver - metabolism | Middle Aged | Ribavirin - therapeutic use | Hepacivirus - genetics | RNA, Viral - analysis | Male | Treatment Outcome | Alanine Transaminase - blood | Interferons - therapeutic use | Hepatitis C - virology | Polymerase Chain Reaction | Adult | Female | Aged | Hepatitis C - pathology | Drug Therapy, Combination | Chronic Disease | Evaluation | Interferon | Hepatitis C | Drug therapy | Ribavirin | Hepatitis | Transplants & implants | Infections | Liver cirrhosis | Drug dosages | Patients | Viral infections | Liver Disease
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection
by Manns, Michael P and Bourlière, Marc and Benhamou, Yves and Pol, Stanislas and Bonacini, Maurizio and Trepo, Christian and Wright, David and Berg, Thomas and Calleja, José L and White, Peter W and Stern, Jerry O and Steinmann, Gerhard and Yong, Chan-Loi and Kukolj, George and Scherer, Joe and Boecher, Wulf O
Journal of Hepatology, ISSN 0168-8278, 2010, Volume 54, Issue 6, pp. 1114 - 1122
Background & Aims BI201335 is a highly specific and potent HCV protease inhibitor. This multiple rising dose trial evaluated antiviral activity and safety in... 
Gastroenterology and Hepatology | Antiviral | Resistant variants | Hepatitis C virus | Pegylated interferon | Ribavirin | PLUS RIBAVIRIN | BILN-2061 | TELAPREVIR | EFFICACY | VX-950 | HEPATITIS-C-VIRUS | IN-VITRO | EARLY ANTIVIRAL ACTIVITY | PEGINTERFERON ALPHA-2A | ATAZANAVIR | GASTROENTEROLOGY & HEPATOLOGY | Antiviral Agents - pharmacokinetics | Hepatitis C - drug therapy | Protease Inhibitors - pharmacokinetics | Humans | Middle Aged | Hepacivirus - genetics | Male | Thiazoles - administration & dosage | Recombinant Proteins | Oligopeptides - adverse effects | Thiazoles - adverse effects | Thiazoles - pharmacokinetics | Protease Inhibitors - pharmacology | Hepatitis C - blood | Ribavirin - administration & dosage | Protease Inhibitors - administration & dosage | Protease Inhibitors - adverse effects | Adult | Female | Hepacivirus - drug effects | Antiviral Agents - pharmacology | Double-Blind Method | Oligopeptides - pharmacokinetics | Carrier Proteins - antagonists & inhibitors | Viral Nonstructural Proteins - genetics | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Interferon-alpha - administration & dosage | Drug Resistance, Viral - genetics | Hepacivirus - enzymology | Antiviral Agents - adverse effects | Hepatitis C - virology | Oligopeptides - administration & dosage | Thiazoles - pharmacology | Oligopeptides - pharmacology | Viral Load - drug effects | Viral Nonstructural Proteins - antagonists & inhibitors | Medical colleges | Antiviral agents | Care and treatment | Safety and security measures | Hotels and motels | Immunodeficiency | Aspartate | Biological response modifiers | HIV (Viruses) | Anti-HIV agents | Complications and side effects | Protease inhibitors | Proteases | Genetic aspects | Hepatitis C | Viral Nonstructural Proteins | Oligopeptides | Polyethylene Glycols | Interferon-alpha | Protease Inhibitors | Drug Resistance, Viral | Antiviral Agents | Viral Load | Life Sciences | Thiazoles | Hepacivirus | Carrier Proteins | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Boceprevir for Untreated Chronic HCV Genotype 1 Infection
by Poordad, Fred and McCone, Jonathan and Bacon, Bruce R and Bruno, Savino and Manns, Michael P and Sulkowski, Mark S and Jacobson, Ira M and Reddy, K. Rajender and Goodman, Zachary D and Boparai, Navdeep and DiNubile, Mark J and Sniukiene, Vilma and Brass, Clifford A and Albrecht, Janice K and Bronowicki, Jean-Pierre and SPRINT2-Investigators and SPRINT-2 Investigators
The New England Journal of Medicine, ISSN 0028-4793, 03/2011, Volume 364, Issue 13, pp. 1195 - 1206
In this trial involving previously untreated patients infected with hepatitis C virus (HCV) genotype 1, boceprevir in combination with peginterferon and... 
MEDICINE, GENERAL & INTERNAL | INTERFERON-ALPHA-2B | TELAPREVIR | PEGINTERFERON ALPHA-2A | CHRONIC HEPATITIS-C | ALPHA-2A PLUS RIBAVIRIN | SCH-503034 | INHIBITOR | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Hepatitis C, Chronic - ethnology | Recombinant Proteins | Polyethylene Glycols - therapeutic use | Viral Load | Serine Proteinase Inhibitors - therapeutic use | Serine Proteinase Inhibitors - adverse effects | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Double-Blind Method | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Anemia - chemically induced | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Proline - therapeutic use | Antiviral Agents - adverse effects | Proline - adverse effects | African Continental Ancestry Group | Hepatitis | Genotype & phenotype | Drug therapy | Human immunodeficiency virus--HIV | Proline | Ribavirin | Hepatitis C, Chronic | Life Sciences | Hépatology and Gastroenterology | Polyethylene Glycols | Interferon-alpha | Anemia | Serine Proteinase Inhibitors | Antiviral Agents | Human health and pathology | RNA, Viral | Hepacivirus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C
by McHutchison, John G and Manns, Michael and Patel, Keyur and Poynard, Thierry and Lindsay, Karen L and Trepo, Christian and Dienstag, Jules and Lee, William M and Mak, Carmen and Garaud, Jean–Jacques and Albrecht, Janice K and International Hepatitis Interventional Therapy Group
Gastroenterology, ISSN 0016-5085, 10/2002, Volume 123, Issue 4, pp. 1061 - 1069
Patient adherence to prescribed antiviral therapy in human immunodeficiency virus infection enhances response. We evaluated the impact of adherence to... 
Polyethylene Glycols | Humans | Middle Aged | Interferons - adverse effects | Hepacivirus - genetics | Genotype | Male | Treatment Outcome | Recombinant Proteins | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Interferon-alpha - administration & dosage | Interferons - administration & dosage | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Ribavirin - administration & dosage | Interferon alpha-2 | Adult | Female | Interferon-alpha - adverse effects | Retrospective Studies | Drug Therapy, Combination
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C
by Poynard, Thierry and McHutchison, John and Manns, Michael and Trepo, Christian and Lindsay, Karen and Goodman, Zachary and Ling, Mei-Hsiu and Albrecht, Janice and PEG-FIBROSIS Project Grp
Gastroenterology, ISSN 0016-5085, 05/2002, Volume 122, Issue 5, pp. 1303 - 1313
Liver fibrosis is an important prognostic factor in patients with hepatitis C. The effect of pegylated (PEG) interferon alone or its combination with ribavirin... 
TRIAL | PLUS RIBAVIRIN | VIRUS-INFECTION | THERAPY | PEGINTERFERON ALPHA-2A | RNA | INITIAL TREATMENT | RISK | GASTROENTEROLOGY & HEPATOLOGY | PROGRESSION | Interferon-alpha - administration & dosage | Liver Cirrhosis - drug therapy | Humans | Ribavirin - administration & dosage | Interferon alpha-2 | Adult | Recombinant Proteins | Drug Therapy, Combination | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Care and treatment | Interferon | Hepatitis C | Liver | Ribavirin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C
by Lindsay, Karen L and Trepo, Christian and Heintges, Tobias and Shiffman, Mitchell L and Gordon, Stuart C and Hoefs, John C and Schiff, Eugene R and Goodman, Zachary D and Laughlin, Mark and Yao, Ruji and Albrecht, Janice K and Hepatitis Interventional Therapy G and Hepatitis Interventional Therapy Group
Hepatology, ISSN 0270-9139, 08/2001, Volume 34, Issue 2, pp. 395 - 403
This international, randomized, active‐controlled, parallel‐group, double‐blind dose‐finding study compared peginterferon alfa‐2b (PegIntron™) to interferon... 
VIRUS-RNA | HCV RNA | PEGINTERFERON ALPHA-2A | SUSTAINED RESPONSE | ALPHA THERAPY | PROTEIN-KINASE | IN-VIVO | RIBAVIRIN | POLYETHYLENE-GLYCOL | GASTROENTEROLOGY & HEPATOLOGY | HISTOLOGIC IMPROVEMENT | Hepatitis C, Chronic - pathology | Liver - pathology | Double-Blind Method | Polyethylene Glycols | Antiviral Agents - therapeutic use | Humans | Middle Aged | Interferon-alpha - therapeutic use | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Recombinant Proteins | Hepatitis C, Chronic - drug therapy | Antiviral Agents - adverse effects | Adult | Female | Aged | Interferon-alpha - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Prevalence and Challenges of Liver Diseases in Patients With Chronic Hepatitis C Virus Infection
by Jacobson, Ira M and Davis, Gary L and El–Serag, Hashem and Negro, Francesco and Trépo, Christian
Clinical Gastroenterology and Hepatology, ISSN 1542-3565, 2010, Volume 8, Issue 11, pp. 924 - 933
Hepatitis C virus (HCV) infections pose a growing challenge to health care systems. Although chronic HCV infection begins as an asymptomatic condition with few... 
Gastroenterology and Hepatology | Burden of Disease | Prevalence | Hepatic Comorbidities | Hepatitis C Virus | UNITED-STATES | INTRAHEPATIC CHOLANGIOCARCINOMA | RISK-FACTORS | FIBROSIS PROGRESSION | HUMAN-IMMUNODEFICIENCY-VIRUS | NATURAL-HISTORY | SUSTAINED VIROLOGICAL RESPONSE | INJECTION-DRUG USERS | INSULIN-RESISTANCE | HEPATOCELLULAR-CARCINOMA DEVELOPMENT | GASTROENTEROLOGY & HEPATOLOGY | United States - epidemiology | Carcinoma, Hepatocellular - epidemiology | Liver Cirrhosis - diagnosis | Carcinoma, Hepatocellular - diagnosis | Humans | Risk Factors | Hepatitis C, Chronic - therapy | Male | Liver Cirrhosis - therapy | Liver Neoplasms - therapy | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - diagnosis | Liver Cirrhosis - epidemiology | Liver Neoplasms - epidemiology | Liver Neoplasms - diagnosis | Carcinoma, Hepatocellular - therapy | Hepatitis C, Chronic - epidemiology | Medical colleges | Care and treatment | Comorbidity | African Americans | Development and progression | HIV (Viruses) | Prevalence studies (Epidemiology) | Liver cancer | Complications and side effects | Baby boom generation | Cytogenetics | Insulin resistance | Hepatitis C | Hepatitis C virus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Antiviral Effect, Safety, and Pharmacokinetics of Five-Day Oral Administration of Deleobuvir (BI 207127), an Investigational Hepatitis C Virus RNA Polymerase Inhibitor, in Patients with Chronic Hepatitis C
by Dominique Larrey and Ansgar W. Lohse and Christian Trepo and Jean-Pierre Bronowicki and Keikawus Arastéh and Marc Bourlière and Jose Luis Calleja and Jerry O. Stern and Gerhard Nehmiz and Nasri Abdallah and Kristi L. Berger and Martin Marquis and Jürgen Steffgen and George Kukolj and BI 207127 Study Grp and BI 207127 Study Group
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 10/2013, Volume 57, Issue 10, pp. 4727 - 4735
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit... 
PROTEASE INHIBITOR | TELAPREVIR | THERAPY | NS3 PROTEASE | MUTATION | RESISTANCE | BOCEPREVIR | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | RIBAVIRIN | IDENTIFICATION | PEGINTERFERON | Hepacivirus - drug effects | Antiviral Agents - pharmacokinetics | DNA-Directed RNA Polymerases - antagonists & inhibitors | Double-Blind Method | Administration, Oral | Antiviral Agents - therapeutic use | Humans | Middle Aged | Hepacivirus - genetics | Male | Hepatitis C, Chronic - drug therapy | Young Adult | Hepacivirus - enzymology | Antiviral Agents - adverse effects | Adolescent | Adult | Female | Aged | Antiviral activity | Life Sciences | Antiviral Agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights